forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Market Size to Hit USD 212.73 Billion by 2035 GLP-1 Analogues Market Size, Share

However, there are some rare but serious risks, including pancreatitis and gallbladder issues

Compiled from earnings calls, press releases, SEC filings, industry media, and verified reporting

All medications come from licensed 503A compounding pharmacies and are HSA/FSA eligible across all 50 states

Our results suggest that thyroid cancer risk should be considered with GLP-1 receptor agonists, particularly in patients treated for 1 to 3 years, Jean-Luc Faillie, MD, PhD , professor and head of the department of medical pharmacology and toxicology at Montpellier University Hospital and University of Montpellier in France, and colleagues wrote

What it can't do: replace your medication, reverse bone loss on its own, substitute for resistance training, or make up for protein deficiency that's affecting multiple systems simultaneously